ArticleAmerican journal of translational research2025
Sirtuin 3 modulation by high phosphates: a potential mechanism in muscle aging and sarcopenia.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- β-Nicotinamide Mononucleotide Inhibits Cellular Senescence in Mouse C2C12 Skeletal Muscle Cells.Journal of aging research · 2026Article
- Molecular Framework of the Onset and Progression of Skeletal Muscle Aging.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the role of elevated phosphate levels in muscle aging, and to elucidate the underlying molecular mechanisms by which high phosphate conditions regulate muscle aging and explore the potential therapeutic role of SIRT3 activation.
methodsYoung (5-month-old) and aged (24-month-old) C57BL/6 mice were compared in terms of body weight, muscle strength, and serum sodium levels. Additionally, C2C12 myoblasts were exposed to 20 mM β-glycerophosphate (BGP) to simulate high phosphate conditions. Cellular senescence was assessed using senescence-associated β-galactosidase (SA-β-GAL) staining and Western blot analysis (P53, P62, and P21). The role of SIRT3 in muscle cell senescence was further investigated by treating C2C12 cells with the SIRT3 activator 2-APQC.
resultsAged mice exhibited significantly higher body weight, reduced grip strength, and elevated serum sodium levels compared to young mice, indicating muscle aging. BGP treatment in C2C12 cells induced cellular senescence, as evidenced by elevated SA-β-GAL activity and upregulation of senescence markers P53, P62, and P21. Furthermore, high phosphate levels impaired cell migration and differentiation. Activation of SIRT3 by 2-APQC alleviated these effects, restoring autophagic activity and reversing muscle cell dysfunction.
conclusionsElevated serum sodium and phosphate levels are associated with muscle aging in mice. High phosphate induces cellular senescence and impairs muscle function, while SIRT3 activation mitigates these effects, highlighting its potential as a therapeutic target for sarcopenia. Dietary phosphate restriction and activation of SIRT3 may represent effective strategies for combating age-related muscle degeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.